Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 3, 1996, Pages 918-922

  Yoo, Sun D ^a   Holladay, John W ^a   Fincher, Timothy K ^a   Baumann, Heinz ^b   Dewey, Michael J ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; IMIPRAMINE;

ANIMAL; ARTICLE; BINDING COMPETITION; C57BL MOUSE; DRUG EFFECT; FEMALE; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; SWIMMING; TRANSGENIC MOUSE;

ANIMALS; BINDING, COMPETITIVE; FEMALE; GLYCOPROTEINS; IMIPRAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; SWIMMING;

EID: 0030096830     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. ABERNETHY, D. R., GREENBLATT, D. J. AND SHADER, R. I.: Imipramine and desipramine disposition in the elderly. J. Pharmacol. Exp. Ther. 232: 183-188, 1985
2. ABRAMSON, F. P. AND LUTZ, M. P.: The kinetics of induction by rifampin of alpha-1-acid-glycoprotein and antipyrine clearance in the dog. Drug Metab. Dispos. 14: 46-51, 1986.
3. BALANT-GORGIA, A. E., BALANT, L. P. AND GARRONE, G.: High blood concentrations of imipramine or clomipramine and therapeutic failure: A case report study using drug monitoring data. Ther. Drug Monit. 11: 415-420, 1989.
4. BELPAIRE, F. M., BOGAERT, M. G., MUGABO, P. AND ROSSEEL, M. T.: Binding to serum alpha-1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation. Br. J. Pharmacol. 88: 697-705, 1986.
5. BICKEL, M H.: Binding of chlorpromazine and imipraraine to red cells, albumin, lipoproteins and other blood components. J. Pharm. Pharmacol. 27: 733-738, 1975.
6. BLOEDOW, D. C., SIMONS, M. A. AND HANSBROUGH, J. F.: Serum drug binding in burn patients. Clin. Pharmacol. Ther. 31: 204, 1982.
7. BRØSEN, K. AND GRAM, L. F. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 43: 400-406, 1988.
8. CHIANG, J. AND ØIE, S.: Pharmacologie activity of prazosin is decreased by alpha-1-acid glycoprotein in vivo. J. Pharmacol. Exp. Ther. 254: 324-329, 1990.
9. DE RICK, D. E , BELPAIRE, F. M. AND BOGAERT, M. G.: Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding, pharmacokinetics and antiarrhythmic effect of lidocaine in the dog. J. Pharmacol. Exp. Ther. 241: 289-293, 1987
10. DEVANE, C. L., RUDORFER, M. V. AND POTTER, W. Z.: Dosage regimen design for cyclic anti-depressants: A review of pharmacokinetic methods. Psychopharmacol. Bull 27: 619-631, 1991.
11. DEWEY, M. J., RHEAUME, C., BERGER, F. G. AND BAUMANN, H.: Inducible and tissue-specific expression of rat alpha-1-acid glycoprotein in transgenic mice J. Immunol 144: 4392-4398, 1990.
12. DUBEY, R. K., MCALLISTER, C. B., INOUE, M. AND WILKINSON, G. R.: Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. J. Clin. Invest. 84: 1155-1159, 1989.
13. FURLANUT, M., BENETELLO, P. AND SPINA, E.: Pharmacokinetic optimization of tricyclic anti-depressant therapy. Clin. Pharmacokinet. 24: 301-318, 1993.
14. HILL, M. D. AND ABRAMSON, P. P.: The effects of phenobarbital and dexamethasone on hepatic cytochrome P-450 and alpha-1-acid glycoprotein in maternal and fetal guinea pigs. Res. Commun. Chem. Pathol. Pharmacol. 69: 33-48, 1990.
15. HUANG, J. AND ØIE, S. : Influence of serum protein binding on hepatic clearance of S-disopyramide in the rabbit. J. Pharm. Pharmacol. 37: 471-475, 1985.
16. KEYLER, J. M., PENTEL, P. R. AND HAUGHEY, D. B.: Pharmacokinetics and toxicity of high-dose human alpha-1-acid glycoprotein infusion. J. Pharm. Sci. 76: 101-104, 1987.
17. KREMER, J. M. H., WILTING, J. AND JANSSEN, L. H. M.: Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40: 1-47, 1988.
18. KRISTENSEN, C. B.: Plasma protein binding of imipramine in patients with rheumatoid arthritis. Eur. J. Clin Pharmacol. 28: 693-696, 1985.
19. MUSCETTOLA, G., GOODWIN, F. K., POTTER, W. Z , CLAEYS, M. M. AND MARKEY, S. P.: Imipramine and desipramine in plasma and spinal fluid. Arch. Gen. Psychiatry 5: 621-625, 1978.
20. 11C-labeled imipramine and its biodistribution in mice: A potential tracer for positron emission tomography. Chem. Pharm. Bull. 37: 3376-3379, 1989.
21. NEMEROFF, C. B., KRISHINAN, K. R. R., BLAZER, D. G., KNIGHT, D. L., BENJAMIN, D. AND MEYERSON, L. R.. Elevated plasma concentrations of alpha-1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site, in depressed patients. Arch. Gen. Psychiatry 47: 337-340, 1990
22. ORSULAK, P. J.: Therapeutic monitoring of antidepressant drugs: Guidelines updated, Ther. Drug Monit. 11: 497-507, 1989.
23. PIAFSKY, K M AND BORGÂ, O.: Plasma protein binding of basic drugs. II. Importance of α-1-acid glycoprotein for individual variation. Clin. Pharmacol. Ther. 22: 544-549, 1977.
24. PORSOLT, R. D.: Behavioral despair revisited. Current Content LS 36: 9, 1993
25. PORSOLT, R. D., BERTIN, A. AND JALFRE, M.: Behavioral despair in rats and mice: Strain differences and the effects of imipramine. Eur. J. Pharmacol. 51: 291 294, 1978.
26. RIANT, P., URIEN, S., ALBENGRES, E., RESOUARD, A. AND TILLEMENT, J. P.: Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain barrier. J. Neurochem. 51: 421-425, 1988.
27. SIMPSON, G. M., WHITE, K. L., BOYD, J. L., COOPER, T. B., HALARIS, A., WILSON, I. C., RAMAN, E. J. AND RUTHER, E.: Relationship between plasma antidepressant levels and clinical outcome for inpatients receiving imipramine. Am. J. Psychiatry 139: 358-360, 1982.
28. SUTFIN, T. A., DEVANE, C. L. AND JUSKO, W. J.: The analysis and disposition of imipramine and its active metabolites in man. Psychopharmacology 82: 310-317, 1984.
29. TSAO, S. C., SUGIYAMA, Y., SAWADA, Y., IGA, T. AND HANANO, M.: Kinetic analysis of albumin-mediated uptake of warfarin by perfused rat iiver. J. Pharmacokinet. Biopharm. 16: 165-181, 1988.
30. VON MOLTKE, L. L., GREENBLATT, D. J. AND SHADER, R. I.: Clinical pharmacokinetics of antidepressants in the elderly. Clin. Pharmacokinet. 24: 141-160, 1993.
31. YASUHARA, M., FUJIWARA, J., KITADE, S., KATAYAMA, H., OKUMURA, K. AND HORI, R.: Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery; role of alpha-1-acid glycoprotein J. Pharmacol. Exp. Ther. 235: 513-520, 1985